Toripalimab after surgery and chemoradiation for head and neck cancer
Part of Cancer clinical trials.
This trial studies toripalimab to lower the risk of the cancer coming back after surgery and additional chemo-radiation. It may help the immune system “finish the job” after your main treatment, especially if you have higher-risk features.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had surgery for locally advanced head and neck squamous cell carcinoma, and your pathology showed higher-risk features
- You finished extra (adjuvant) radiation (with or without chemo) within the last 2 months
- You are age 18 to under 70 and can do daily activities normally (ECOG 0 or 1)
- Your cancer has measurable disease on scans (RECIST 1.1)
- Your recent blood tests (within 14 days) show your liver, kidneys, bone marrow, and blood counts are strong enough
- You can use the required birth control and you are willing to sign consent and follow all study visits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests toripalimab (an immunotherapy) given before surgery for untreated head and neck squamous cell carcinoma, either alone or with chemotherapy. The goal is to shrink or control the cancer earlier and see if it improves outcomes for people who plan curative surgery.
This trial tests a combination of two drugs (MRG003 and Toripalimab) given before surgery to shrink head and neck cancer tumors. It's for people with a specific type of cancer that hasn't been treated before and is PD-L1 positive.
This trial tests whether adding the immunotherapy drug toripalimab to standard chemoradiation before surgery helps people with a type of esophageal cancer. It is for patients whose cancer has not spread to other organs and who have not had treatment before.
This study tests whether adding a drug called toripalimab after standard chemoradiation can help older adults with esophageal cancer. The goal is to see if this treatment can keep the cancer from coming back after initial therapy.
This trial tests adding the immunotherapy drug toripalimab to chemotherapy after surgery for non-small cell lung cancer (NSCLC). It is for patients who either had no treatment before surgery or had chemo-immunotherapy before surgery and still have signs of cancer in their lymph nodes. The goal is to see if this combination helps prevent cancer from coming back.
This Phase 2 study tests whether giving low-dose radiation before surgery—along with chemotherapy and an immunotherapy drug—can work better and be safe for treating locally advanced head and neck squamous cell cancer. It may help shrink tumors before surgery and reduce the chance of the cancer coming back.
Hear when a new Head and Neck Squamous Cell Carcinomas trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.